Move will open trial for Therapeutic Cancer Vaccine (K9-ACV) to more Veterinarians across the United States.
Lexington, KY (PRWEB) July 15, 2015
MediVet Biologics, a global leader in Veterinary cell therapy and biologic solutions has completed construction on an in-house laboratory for the company’s K9-ACV service or canine autologous cancer vaccine. Since January 1st 2015 the service has been based at the University of Kentucky and offered a new treatment avenue for small select group of Veterinarians encountering cancerous resectable canine tumors. Dr. John Yannelli and his team have completed standard operating procedures and protocols in order to move the laboratory on site with MediVet Biologics.
The announcement comes off the back of the AVMA Summit in Boston this past weekend where Medivet Biologics shared some very positive data from the early treatment groups.
“I am excited to what the future holds in canine medicine specifically as it relates to immunotherapy”, said Dr. Yannelli. “My work has been dedicated to treating the human patient and from what I have seen immunotherapy has never left as a treatment option, the knowledge and expectations have evolved.”
“Moving this service to MediVet Biologics”, Yannelli continued, “will open more opportunity for Veterinarians to access this technology that may be seeking it. We know that diagnostic measures need to continuously evolve in the animal health space for earlier detection, although we feel that this vaccine will be effective and reach a price point for multi modal treatment plans when needed.”
K9-ACV stands for Canine Autologous Cancer Vaccine. Cancer cells can be recognized as foreign by the immune system if those cancer cells are presented to the immune system in a manner that “breaks immune tolerance.” Decades of research in mouse and human models have shown that tumor cells are very much like normal cells in that they express self-antigens that the body is taught to ignore early in development and throughout life. An immunosuppressive environment produced by growing tumors promotes an immune response toward the tumor that is ineffective, allowing the tumor to grow unchecked.
An appropriately designed tumor vaccine can break this cycle of tumor immunosuppression, generating tumor-specific immune cells that have effective anti-tumor reactivity, improving survival and quality of life in veterinary patients. The K9-ACV vaccine is specifically designed to make the patient’s tumor appear foreign, thus inducing an effective anti-tumor immune response, similar to an immune response against viral or bacterial infections.
During excision the Veterinarian simply needs to harvest 5 grams of the tumor in order to ship to lab for processing of the vaccine. The vaccine is processed and undergoes a series of sterility tests before it is returned to the Veterinarian clinic for intradermal application. The vaccine is administered over a 60 day period.
About MediVet Biologics:
MediVet Biologics is a global leader in veterinary regenerative medicine and biological solutions. With corporate offices in Central, Kentucky, and Sydney, Australia and cases performed in over 29 countries around the world. MediVet’s accomplishments in the regenerative medicine market have given way to an incredible pipeline of technological advancements and the ability to successfully bring those animal health products to market. MediVet is the only Veterinary Regenerative Medicine Company to have multiple collaborative university studies further validating current technology and product pipelines. MediVet prides itself on having the latest cutting edge technologies to allow Veterinarians the ability to ease their patient’s pain. To learn more about MediVet Biologics, call 1.800.365.9168 or visit us at http://www.medivetbiologics.com
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/07/prweb12851941.htm